Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT03184870 : A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors

Male or<br/>FemaleGender Male or

Closed (no longer recruiting)Status Closed (no longer recruiting)

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer

Systemic therapy | Bowel (colorectum),Stomach and upper gastrointestinal tractColorectum,Pancreas

Trial Overview Read MoreRead more

This phase I/II trial is evaluating the safety and effectiveness of an oral drug (BMS-813160) alone or in combination with immunotherapy (Nivolumab) and/or chemotherapy in patients with advanced solid cancers, particularly colorectal cancer or pancreatic cancer.

This trial is treating patients with colorectal or pancreatic cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors

Commercial Sponsor

Bristol-Myers Squibb (BMS)


This is a non-randomised trial, in which patients will be assigned to one of seven experimental arms, receiving BMS-813160 alone or as a combination therapy. Combination therapies will include one or more of the following: Nivolumab, Nab-paclitaxel, Gemcitabine, 5-fluoroucil (5-fu), leucovorin and/or Irinotecan.

Not Recruiting Hospitals Read MoreRead more


Cabrini Education and Research Precinct
Micheleine Uhe
(03) 9508 3481

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.